Objective To evaluate the therapeutic effect of novel β-catenin-binding drug SAHPA1 on postmenopausal osteoporosis animal models. Methods C57 female mice were selected and divided into 3 groups (n=5): Sham group, osteoporosis model group (OP group), and osteoporosis model treatment group (Treat group). The mice in the Sham group only underwent surgical incision exposing bilateral ovaries, while the mice in the OP and Treat groups underwent bilateral ovariectomy and the ovariectomized osteoporosis mouse models were established. Then the mice in the Treat group were immediately treated with SAHPA1 (10 mg/kg) by daily intramuscular injection, and those in the Sham and OP groups were injected with the same dose of saline daily. The morphology of trabecular bone in the femur metaphyseal bone in mice was observed and the morphometric analysis was performed by bone tissue sections with H-E staining and micro-CT. The therapeutic effect of SAHPA1 on osteoporosis in ovariectomized mice models was also evaluated. Results The bone mineral density (BMD), trabecular bone number (Tb.N) and trabecular bone thickness (Tb.Th) of mice in the OP group were significantly lower than those in the Sham group (P<0.05). The BMD and Tb.N of mice in the Treat group were significantly higher than those in the OP group (P<0.05), while there was no significant difference in Tb.Th between the two groups (P>0.05). Conclusion The novel β-catenin-binding drug SAHPA1 has a certain therapeutic effect on postmenopausal mice with osteoporosis.